We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GSK Gsk Plc

-15.00 (-0.91%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -15.00 -0.91% 1,636.00 1,638.00 1,639.00 1,661.50 1,635.50 1,656.50 4,329,161 16:35:12
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.69 67.46B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,651p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £67.46 billion. Gsk has a price to earnings ratio (PE ratio) of 13.69.

Gsk Share Discussion Threads

Showing 32951 to 32974 of 33100 messages
Chat Pages: 1324  1323  1322  1321  1320  1319  1318  1317  1316  1315  1314  1313  Older

Technical analysts use support and resistance levels to identify price points on a chart where the probabilities favour a pause or reversal of a prevailing trend.

Support occurs where a downtrend is expected to pause due to a concentration of demand.

Resistance occurs where an uptrend is expected to pause temporarily, due to a concentration of supply.

Market psychology plays a major role as traders and investors remember the past and react to changing conditions to anticipate future market movement.

Support and resistance areas can be identified on charts using trendlines and moving averages.

Glaxo part of GS so called Granola stocks, Glaxo, Roche, Astra Nordisk, etc. Glaxo will be 1950p, but for me Novo Nordisk is the big hitter, fat buster drug, making billions, doubler I reckon.
It will, but by the looks of things, with little resistance to 18, the share price is keen to get there pretty quick!
Just looked back 20 years at the chart and looks like breaking 18 will be tough
having a little rest before moving on up
The healthcare team at Citi has turned positive on GSK PLC (LSE:GSK, NYSE:GSK) for the first time in seven years.

Pushing the investment bank's analysts over the precipice to 'buy' was the outlook for belantamab mafodotin, (known as Blenrep for short), the drug giant's treatment for the blood disease myeloma.

"Our upgrade is based not only on Blenrep’s underappreciated revenue potential but also the cumulative impact of the multiple incremental positives ranging from Zantac liability outlook, RSV/ Shingrix, astute business development, and increasingly positive ViiV outlook post dolutegravir loss of exclusivity," Citi said in a note to clients.

Its upbeat stance on Blenrep stems from the "compelling" results from GSK's DREAMM-7 phase III clinical trial. Assuming the next set of study results are positive, then the drug "has a significant role for at least the next five years as a standard of care for refractory myeloma patients, particularly for older patients that are either poor candidates for CAR-T or bispecifics, or who receive their treatment within the community".

In early trade, the shares were up 14.34p at 1,640.74p. Citi reckons the stock is worth £21 (up from £17).

Here the link
That's the first time in 7 years Citi has a buy on GSK, 2100p target.
Citigroup raises target to 2100p from 1700p
Did you really? I'm not sure why you had any holding here when you keep saying APH are the only pharma worth holding. I had a Quick Look at them and they don't really have many products do they. Very limited growth I would think
That's about right and there's a couple of brokers that also agree with you (though they don't give a target time frame) ...;0)
Out of interest, what are peoples' price targets for this in the next year? I'm looking for £19.50, which seems possible once the Zantac fog is cleared and if revenue/ pipeline progress continues as per recently..
Hmmm ... not exactly in the same league, though?
Sold half of my investment & going to buy APH ( growing health care company)
GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Fast track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

The designation was requested based on the potential for bepirovirsen to address an unmet medical need for CHB, a serious and life-threatening condition. Data from the phase IIb trials B-Clear and B-Sure, which evaluated the efficacy, safety and durability of response of bepirovirsen in people with CHB, were submitted in support of the application. A confirmatory phase III programme, B-Well, is ongoing.

Only 18months of misery, I’ve had 10years of it, hopefully that Lady will pull it together,£30 one day
Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in PROGRESS-AD, the global Phase 2 clinical trial of AL101/GSK4527226 in patients with early Alzheimer’s disease (AD), including mild cognitive impairment and mild dementia due to AD. AL101 is an investigational human monoclonal antibody designed to block and downregulate the sortilin receptor to elevate the level of progranulin in the brain in a manner similar to investigational latozinemab but with different pharmacokinetic (PK) and pharmacodynamic (PD) properties. Alector and GSK are co-developing and will be co-commercializing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
Jefferies raises target price to 1950p from 1900p
From yesterdays questor column

"GSK is performing well despite the legal clouds that hang over it
Questor share tip: more of its vaccines are proving their worth and the company’s valuation fails to reflect punchy growth forecasts

Russ Mould

6 February 2024 • 6:00am

Strong full-year numbers last week, a planned dividend rise in 2024 and upgraded medium-term growth and profit forecasts all support our confidence in GSK, where a blossoming drugs pipeline gives additional visibility and increases the chances of some reward for readers in the form of both capital appreciation and income.

A fourth dismissal or settlement of lawsuits relating to the heartburn treatment Zantac is also encouraging.

While the legal cloud regarding the drug and its allegedly carcinogenic side-effects is far from fully lifted, the market’s worst fears regarding possible liabilities are yet to be borne out and the shares still trade some 9pc below highs reached almost two years ago.

GSK still faces a lengthy list of cases, but the more that are settled, the greater the chance that investors can again focus on the day-to-day business, which is performing well.

The launch of the respiratory syncytial virus vaccine Arexvy is going well, judging by 2023’s sales tally of £1.2bn, which is already 4pc of the group total.

That nicely supplements the £3.4bn revenues from shingles vaccine Shingrix and helps the company to get over its embarrassing failure to match Pfizer, Moderna and AstraZeneca in the race to find a Covid vaccine.

GSK now has 71 vaccines and speciality medicines in its drug development pipeline, including 18 at the Phase III stage, and is hoping for a dozen to come to market from 2025 onwards in areas such as HIV, oncology and respiratory conditions.

This roadmap presumably underpins the upgrade to medium-term sales and profits growth targets offered by chief executive Dame Emma Walmsley alongside the full-year figures.

GSK now expects compound annual growth rates of 7pc in revenues and 11pc in earnings between 2021 and 2026. Such a rate of progress would suggest that a multiple of barely 12 times forecast earnings looks decent value, especially when it is supported by a yield of 3.6pc, based on management’s guidance for a 60p-a-share dividend in 2024.

GSK still looks like good value. Hold."

On a lovely run here now.., see if we can get to somewhere near to where the share price was before the HLN split and consolidation price of c1800 summer 2022..
laurence llewelyn binliner
Decent showing in a down market.
DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma.

· 59% reduction in risk of disease progression or death observed in patients with Blenrep combination versus standard of care daratumumab combination

· 36.6 months of median progression-free survival observed with Blenrep combination versus 13.4 months in daratumumab combination

· Strong, clinically meaningful trend in overall survival favouring Blenrep combination was observed with 43% reduction in risk of death

GSK's RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk.

· Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population

· Adults aged 50 and above with underlying medical conditions are at increased risk for RSV disease.

· GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk

· US FDA has set a Prescription Drug User Fee Act action date of 7th June 2024.

GSK's regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration.

· Shingrix already approved in China for adults aged 50 years and over

· Application could expand populations eligible to benefit from protection against shingles to include adults with an increased risk of the disease

· Approximately six million cases of shingles in China each year, with the incidence over three times higher for adults at increased risk compared to the general population

Chat Pages: 1324  1323  1322  1321  1320  1319  1318  1317  1316  1315  1314  1313  Older

Your Recent History

Delayed Upgrade Clock